Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule.

摘要: PURPOSEWe performed a phase II study of single-agent carboplatin against metastatic/locally advanced breast cancer using pharmacokinetically guided dose schedule, to define further the potential role for this agent in combination and high-dose therapy.PATIENTS AND METHODSForty patients with were treated based on glomerular filtration rate (GFR) achieve an area under concentration-versus-time curve (AUC) 7 mg/mL.min, each course repeated at 4-week intervals. The median age was 57 years (range, 37 71).RESULTSTen achieved partial response (PR), overall 25% (95% confidence interval, 13% 41%). One 13 (8%) previously responded compared nine 27 (33%) who had not received previous chemotherapy. Median duration 18 weeks 10 68). World Health Organization (WHO) grade 2 or greater toxicity as follows: anemia, 42%; leukopenia, 20%; thrombo...